Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523155 | 1.00 | GAA (0.53) | GAAALDH1A1KDM4ELMNATDP1 | |
| SCHEMBL15161308 | 0.80 | GAA (0.48) | GAAALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL12791416 | 0.79 | GAA (0.55) | GAAALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL969793 | 0.79 | TSHR (0.47) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14136794 | 0.79 | TSHR (0.47) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8216463 | 0.79 | TSHR (0.47) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL15630701 | 0.78 | CA1 (0.48) | ALDH1A1KMT2A | |
| SCHEMBL30136653 | 0.78 | CA1 (0.48) | ALDH1A1KMT2A | |
| SCHEMBL14136782 | 0.77 | TSHR (0.44) | GAAALDH1A1KDM4ELMNAKMT2A | |
| Hydrochloric Acid SCHEMBL928631 | 0.77 | TSHR (0.46) | GAAALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | GAA 3527/4885ALDH1A1 4659/4885KDM4E 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.